Find out how integrative chiropractic care for OUD combines treatment options to support patients with opioid use disorder effectively.
Abstract
Opioid use disorder (OUD) is a chronic neurobiological condition, and medications for opioid use disorder (MOUD) remain the treatment with the strongest evidence for reducing overdose death. In clinical practice, however, a large share of opioid exposure begins with, and is maintained by, untreated or poorly treated musculoskeletal pain. Disc injury, facet irritation, sciatica, guarded posture, myofascial trigger points, and deconditioning create a pain-opioid loop. Opioids then add their own musculoskeletal injuries: opioid-induced hyperalgesia, withdrawal myalgias, falls, muscle loss, and, in people who inject, osteomyelitis and septic arthritis.
This educational post explains how integrative chiropractic care acts on the musculoskeletal system to interrupt that loop. Spinal and extremity joint care, soft-tissue treatment, neuromuscular re-education, graded loading, and pain neuroscience education reduce nociceptive input, restore motion, and lower the sympathetic arousal that amplifies both pain and craving. These services do not replace methadone, buprenorphine, or naltrexone. They reduce the biomechanical reasons patients reach for opioids and make it easier to stay in MOUD and rehabilitation.
Clinical observations from my practice at Injury Medical Clinic PA, shared at sciatica.clinic and on LinkedIn, are paired with current public-health figures and peer-reviewed evidence. Medical safety, diagnostics, and medication management are overseen by our Medical Director, Dr. Maria Guadalupe Cardenas, MD, board-certified in internal medicine (NPI 1164426749; Texas MD License J2933).
The Musculoskeletal Path Into Opioid Use
Many patients I see in El Paso did not set out to develop OUD. They arrived with a disc herniation, a work injury, sciatica, a facet syndrome, or months of guarding after a motor-vehicle collision. Opioids were started for a real nociceptive problem. When the joint, disc, or nerve root was never rehabilitated, the prescription became the coping strategy.
That pattern matches what we know about pain and OUD. Central sensitization, the amplification of pain signals inside the spinal cord and brain, tracks with pain as a reason for starting opioids, continuing them, escalating the dose, delaying treatment, and relapsing (Hall et al., 2022). Chronic noncancer low back pain is one of the most common reasons opioids are still prescribed, even though they have limited benefit for function and a clear risk of dependence.
Public-health numbers have improved, but they remain severe. Provisional data from the CDC National Center for Health Statistics estimate 69,973 drug overdose deaths in the United States in 2025, down almost 14% from 81,313 in 2024. Deaths involving opioids fell from an estimated 55,296 in 2024 to 44,564 in 2025 (Centers for Disease Control and Prevention [CDC], 2026). These counts are provisional and will change as records are completed. In the 2024 National Survey on Drug Use and Health, 4.8 million people aged 12 or older had a past-year opioid use disorder, and only 17% (about 818,000 people) received MOUD (Substance Abuse and Mental Health Services Administration [SAMHSA], 2025). Most people who meet criteria are untreated. A clinic that can treat the spine and the substance use disorder in the same building is positioned to close part of that gap.
What OUD and Opioids Do to the Musculoskeletal System
OUD is not only a brain disease. It remakes how the musculoskeletal system moves, hurts, and heals. Understanding those body-level changes is what makes chiropractic care relevant.
Guarded motion and joint restriction. Pain teaches the nervous system to lock segments. Lumbar facets stop gliding. Hips stop extending. The thorax stiffens. Patients stand with a posterior pelvic tilt, a flexed trunk, and a short stride. That pattern unloads an irritable disc or nerve for a few minutes and overloads the same tissues for the rest of the day. Over months, capsule thickening, muscle inhibition, and loss of proprioception turn an acute injury into a chronic pain generator.
Peripheral and central sensitization. Injured discs, facet capsules, and paraspinal muscles release substance P, calcitonin gene-related peptide, tumor necrosis factor-alpha, interleukin-1 beta, and prostaglandin E2. Those mediators lower the firing threshold of A-delta and C fibers. Repeated C-fiber input opens NMDA channels in the dorsal horn, the wind-up phenomenon, so ordinary touch and joint motion are read as pain. Opioid-induced hyperalgesia pushes the same system further: the drug that once relieved pain begins to heighten it (Hall et al., 2022).
Withdrawal myalgias and autonomic surge. Opioid withdrawal is a musculoskeletal event as much as a psychological one. Bone and joint aches, restless legs, piloerection, sweating, and tremor are scored on the Clinical Opiate Withdrawal Scale because they are reliable. Sympathetic overdrive tightens paraspinal and scalene muscles, worsens sleep, and makes cravings feel physical. Patients often describe the urge to use as “my back is on fire” rather than as a thought.
Deconditioning and sarcopenia. Sedation, poor sleep, and low protein intake strip type II muscle. Gluteal inhibition and a weak deep core leave the lumbar spine without a muscular brace. The disc and facets take the load the muscles should have shared. Falls from sedation add sprains, compression fractures, and new opioid prescriptions.
Injection-related bone and joint infection. People who inject are at risk for septic arthritis and osteomyelitis, often from Staphylococcus aureus, including MRSA. These are medical emergencies, not adjustment candidates, until infection is controlled. After surgical or antibiotic care, residual stiffness, gait change, and chronic pain become rehabilitation problems. Xylazine, an alpha-2 adrenergic adulterant, adds ischemic skin necrosis that limits weight-bearing and shoulder or hip motion (Friedman et al., 2022). Naloxone does not reverse xylazine. Airway support still comes first.
Comorbid pain syndromes. Sciatica, cervical radiculopathy, thoracic stiffness, temporomandibular guarding, and widespread nociplastic pain commonly travel with OUD. Untreated, each one is a relapse trigger. Treated, each one is a recovery milestone the patient can feel.
How Chiropractic Care Changes the Musculoskeletal System
In this model, chiropractic care is not a single thrust. It is a sequence aimed at the tissues that keep sending danger signals.
Joint motion. High-velocity, low-amplitude adjustments and slower mobilizations stimulate Type I and Type II mechanoreceptors in the capsule and paraspinal muscles. Large-diameter A-beta fibers enter the dorsal horn and activate inhibitory interneurons that reduce C-fiber traffic, the classic gate-control effect. Restored segmental motion also unloads a swollen facet, improves disc nutrition through movement, and gives the brain an accurate position sense it had lost. Supraspinally, that mechanoreceptor barrage can engage descending inhibition from the periaqueductal gray and rostral ventromedial medulla.
Muscle and fascia. Instrument-assisted soft-tissue work, ischemic compression of trigger points, and graded stretching reduce local chemical irritation and restore glide between muscle and nerve. In sciatica, the problem is often both a lumbar segment and a tethered nerve. Hip hinge mechanics, core bracing, and neurodynamic glides reduce mechanical tension on the nerve root without asking the patient to “push through” electric pain.
Motor control. Neuromuscular re-education retrains gluteal activation, diaphragmatic breathing, and anti-rotation control of the lumbar-pelvic-hip complex. The goal is a spine that can share load. Patients who can hinge, carry, and walk a shift have fewer end-of-day flares, and fewer flares mean fewer reasons to add a nonprescribed opioid.
Autonomic tone. Withdrawal and chronic pain both raise sympathetic drive. Gentle thoracic mobilization, rib-cage motion, and paced breathing lower that drive. In practice, I see sleep onset improve after thoracic and cervical mobility work, and sleep is one of the strongest non-drug buffers against next-day pain and craving.
Pain neuroscience education. Explaining sensitization in plain language reduces catastrophizing. Catastrophizing is not a character flaw. It is a prediction the nervous system makes when every bend has hurt for a year. Graded exposure replaces that prediction with new evidence.
The evidence that this sequence lowers opioid exposure is real and should be stated at its actual strength. Among New Hampshire adults with office visits for noncancer low back pain, receipt of chiropractic services was associated with a 55% lower likelihood of filling an opioid prescription (odds ratio 0.45; 95% CI 0.40-0.47) (Whedon et al., 2018). In active-duty service members, adding chiropractic care to usual medical care produced moderate short-term gains in pain and disability and lower self-reported pain-medication use at six weeks (odds ratio 0.73; 95% CI 0.54-0.97) (Goertz et al., 2018). A 2025 systematic review and meta-analysis of 2 trials and 18 cohort studies found very low-certainty evidence that chiropractic care may reduce the odds of receiving prescription opioids for noncancer spine pain by about 64% (OR 0.36; 95% CI 0.25-0.52), with a larger association when care started within 30 days of presentation (Emary et al., 2025). Early musculoskeletal care appears to matter more than late care. These studies are mostly observational. They support chiropractic care as a way to reduce opioid exposure for spine pain. They do not show that adjustment treats OUD by itself.
Where Chiropractic Care Fits With MOUD
MOUD is the mortality intervention. Methadone and buprenorphine cut death during treatment by roughly half compared with no medication or with treatment stopped (Sordo et al., 2017). After a nonfatal overdose, methadone and buprenorphine are associated with lower all-cause and opioid-related mortality; naltrexone has a different evidence profile and a detoxification requirement (Larochelle et al., 2018; Lee et al., 2018). Buprenorphine is a partial mu-opioid agonist with a ceiling on respiratory depression and a higher receptor affinity than fentanyl, which is why a stable dose can blunt the effect of a relapsed full agonist (SAMHSA, 2021). Office-based prescribing no longer requires an X-waiver (SAMHSA, 2023).
Chiropractic care does not compete with pharmacology. It handles the reason many patients say the medication is “not enough”: the back, the leg, the neck, the inability to work. In my clinic, the sequence is deliberate.
-
Safety first: naloxone in hand, fentanyl and xylazine risk discussed, infectious-disease screening, and no punitive response to a positive urine drug test.
-
MOUD selection and induction under Dr. Cardenas’s medical direction. For fentanyl-exposed patients,s I favor micro-induction, the Bernese method, because fentanyl’s fat storage makes standard induction more likely to precipitate withdrawal (Ahmed et al., 2021).
-
Only after withdrawal and cravings begin to settle do we load the spine. Early sessions stay gentle, so we don’t spike autonomic arousal during induction.
-
As the dose stabilizes, we add segmental care, hip-hinge drills, neurodynamic work, and graded strength.
-
Long-acting injectables such as Sublocade or Brixadi can simplify adherence while rehabilitation progresses.
Withholding MOUD because a patient is still using is not harm reduction. Withholding rehabilitation because a patient is on buprenorphine is also a mistake. The two should run together.
Clinical Observations From Practice
These observations come from integrative care at Injury Medical Clinic PA and are discussed in the public clinical essays at sciatica.clinic and on my LinkedIn profile. They are practice patterns, not trial results.
Patients who stay in structured rehabilitation alongside MOUD show less pain catastrophizing and lower craving intensity. Function usually improves before mood does. That order matters. A patient who can walk symmetrically has new evidence that the body is recoverable, and that evidence supports the next buprenorphine dose and the next therapy visit.
Sciatica is the clearest example. Stabilizing OUD with buprenorphine is what makes neurodynamic flossing, segmental stabilization, and graded loading possible. Before stabilization, patients guard, spike, and leave. After stabilization, hip-hinge mechanics, core bracing, and nerve glides can decompress an irritable root and reduce peripheral sensitization. I repeatedly see gait symmetry return before the patient describes the leg as “fine.”
Lumbar disc-related radicular pain, often at L4-L5, responds to targeted stabilization and hip-hinge retraining. In those cases, buprenorphine doses tend to stay stable rather than climb, because breakthrough pain episodes drop. Facet-mediated low back pain responds to segmental mobilization plus anti-rotation core work, with fewer opioid-seeking days between visits. Thoracolumbar stiffness often feeds sympathetic arousal; gentle mobilization and diaphragmatic breathing reduce the panic-driven craving I see in the first weeks of withdrawal stabilization.
Sleep is a practical marker. Patients report easier sleep onset and fewer night wakes after thoracic and cervical mobility work, especially when rib-cage motion is restored. Better sleep tracks with better MOUD adherence and fewer missed psychotherapy visits. I do not claim the adjustment treats insomnia. I claim a stiff, sympathetic thorax is one reason these patients cannot downshift at night.
Fentanyl-era inductions have changed the timing of hands-on care. Micro-induction has been the difference for patients who previously failed a standard start because of precipitated withdrawal. During the micro-induction week,k I keep chiropractic input light: breathing, gentle neurodynamic drills, and positional relief. Once cravings fall, often around a stable dose near 16 mg of sublingual buprenorphine in typical cases, we add spinal care, hip-hinge drills, and sleep regularization. Weekly Brixadi has been a useful bridge for patients who are not ready for a monthly commitment. Transition to monthly Sublocade then supports the strength phase, with attention to end-of-interval symptom drift. Proactive oral hygiene counseling at buprenorphine initiation has reduced later reports of dental sensitivity.
A recurring case shape is the laborer with lumbar radicular pain and daily fentanyl exposure. Micro-induction, naloxone, and a low early dose come first. Diaphragmatic breathing and non-provocative nerve mobility come second. Spinal adjustment, posterior-chain strength, and graded conditioning come third, aimed at tolerating a full shift. The functional goal, not a pain score of zero, is what predicts retention.
Comorbidities We Treat in the Same Plan
Musculoskeletal comorbidities of OUD are not side issues.
-
Withdrawal myalgia and restless legs ease when the dose is adequate and when paraspinal guarding is treated. Chiropractic care does not replace a correct buprenorphine or methadone dose.
-
Opioid-induced hyperalgesia is a signal to stop escalating full agonists and to rebuild descending inhibition with movement, education, and MOUD rather than with more short-acting opioids. Treat deconditioning with protein-adequate meals, daily walking, and progressive posterior-chain loading once infection and cardiac status are clear.
-
Treat post-infection stiffness after septic arthritis or endocarditis with rehabilitation, coordinated with the physician who cleared the patient.
-
Xylazine wounds need wound care and medical management first. We protect load-bearing and shoulder motion around dressings; we do not mobilize through active necrosis.
-
Co-use of benzodiazepines and alcohol raises overdose risk. We do not add sedating manual techniques that leave a patient orthostatic. Anxiety and insomnia are approached with breathing, sleep timing, and behavioral referral.
-
Pregnancy changes tissue laxity and balance. Methadone and buprenorphine are the pharmacologic standards (American College of Obstetricians and Gynecologists, 2017). Manual care stays gentle, and obstetric coordination stays with Dr. Cardenas and the obstetric team.
The Clinic Model
Injury Medical Clinic PA is built so the musculoskeletal plan and the medical plan are not separate referrals that never meet.
Dr. Cardenas provides diagnostic leadership, internal-medicine management, MOUD selection, EKG review before methadone, liver monitoring where injectables or naltrexone require it, and infectious-disease screening. I provide the neuromusculoskeletal examination, chiropractic care, functional-medicine support, and rehabilitation direction, and I prescribe buprenorphine and naltrexone under that medical collaboration. Personal-injury rehabilitation sits in the same pathway, because the collision that started the opioid prescription is often still the pain generator.
Harm reduction is standard, not optional: naloxone for every patient at risk, coordination with syringe service programs, fentanyl and xylazine test-strip education, and the explicit rule that a return to use is data, not discharge (National Harm Reduction Coalition, n.d.; CDC, n.d.). Motivational interviewing, using open questions, affirmations, reflections, and summaries, is how we set the next mobility goal without a lecture (Miller & Rollnick, 2013). Relapse is treated as a stage in a chronic illness, not a failure of character (Prochaska & Velicer, 1997).
What This Does Not Claim
Chiropractic care does not reverse an overdose, occupy mu-opioid receptors, or substitute for methadone, buprenorphine, or naltrexone. It does not treat endocarditis, necrotizing infection, or pregnancy-related OUD without medical care. Observational associations between chiropractic visits and fewer opioid fills can be affected by who seeks that care. The honest claim is narrower and still clinically important: restoring joint motion, muscle capacity, nerve mobility, and autonomic balance removes musculoskeletal drivers of opioid use, lowers craving tied to pain flares, and makes MOUD and counseling easier to stay in. That is how chiropractic care reduces OUD risk in an integrative clinic. It treats the body that has been using opioids to solve a mechanical problem.
References
Ahmed, S., Bhivandkar, S., Lonergan, B. B., & Suzuki, J. (2021). Microinduction of buprenorphine/naloxone: A review of the literature. The American Journal on Addictions, 30(4), 305-315.
American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy (Committee Opinion No. 711). Obstetrics & Gynecology, 130(2), e81-e94.
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing.
American Society of Addiction Medicine. (2020). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. Journal of Addiction Medicine, 14(2S), 1-91.
Centers for Disease Control and Prevention. (n.d.). Syringe services programs. U.S. Department of Health and Human Services.
Centers for Disease Control and Prevention. (2026, May 13). U.S. overdose deaths decrease for third consecutive year in 2025. National Center for Health Statistics.
Emary, P. C., Corcoran, K. L., Coleman, B. C., Brown, A. L., Ciraco, C., DiDonato, J., Wang, L., Couban, R. J., Sud, A., & Busse, J. W. (2025). Impact of chiropractic care on opioid use for noncancer spine pain: Systematic review and meta-analysis. PAIN Reports, 11(1), e1374.
Friedman, J., Montero, F., Bourgois, P., Wahbi, R., Dye, D., Goodman-Meza, D., & Shover, C. (2022). Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug and Alcohol Dependence, 233, 109380.
Goertz, C. M., Long, C. R., Vining, R. D., Pohlman, K. A., Walter, J., & Colter, I. (2018). Effect of usual medical care plus chiropractic care vs usual medical care alone on pain and disability among US service members with low back pain: A comparative effectiveness clinical trial. JAMA Network Open, 1(1), e180105.
Hall, O. T., Teater, J., Rood, K. M., Phan, K. L., & Clauw, D. J. (2022). Central sensitization in opioid use disorder: A novel application of the American College of Rheumatology Fibromyalgia Survey Criteria. PAIN Reports, 7(4), e1016.
Jimenez, A. (n.d.). Clinical observations on sciatica, neuromusculoskeletal rehabilitation, and integrative pain care. Sciatica Pain and Treatment Clinic.
Jimenez, A. (n.d.). Professional profile and clinical updates. LinkedIn.
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137-145.
Lee, J. D., Nunes, E. V., Jr., Novo, P., Bach, V., Bailey, G. L., Bhatt, S., & Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: B OT): A multicentre, open-label, randomized controlled trial. The Lancet, 391(10118), 309-318.
Miller, W. R., & Rollnick, S. (2013). Motivational interviewing: Helping people change (3rd ed.). Guilford Press.
National Harm Reduction Coalition. (n.d.). Overdose prevention. National Harm Reduction Coalition.
Prochaska, J. O., & Velicer, W. F. (1997). The transtheoretical model of health behavior change. American Journal of Health Promotion, 12(1), 38-48.
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.
Substance Abuse and Mental Health Services Administration. (2021). Medications for opioid use disorder (Treatment Improvement Protocol 63, Publication No. PEP21-02-01-002). U.S. Department of Health and Human Services.
Substance Abuse and Mental Health Services Administration. (2023). Waiver elimination (MAT Act). U.S. Department of Health and Human Services.
Substance Abuse and Mental Health Services Administration. (2025). Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health (HHS Publication No. PEP25-07-007). Center for Behavioral Health Statistics and Quality.
Whedon, J. M., Toler, A. W. J., Goehl, J. M., & Kazal, L. A. (2018). Association between utilization of chiropractic services for treatment of low-back pain and use of prescription opioids. Journal of Alternative and Complementary Medicine, 24(6), 552-556.
SEO Tags
opioid use disorder, OUD, chiropractic care, musculoskeletal pain, sciatica, central sensitization, opioid-induced hyperalgesia, buprenorphine, methadone, naltrexone, MOUD, harm reduction, naloxone, low back pain, radiculopathy, neurodynamic glides, hip hinge, core bracing, autonomic regulation, withdrawal myalgia, integrative rehabilitation, Injury Medical Clinic PA, El Paso Texas, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, non-opioid pain management, fentanyl, xylazine, pain neuroscience education, recovery capital